Phase 2 N=63 Study Of Sunitinib With Capecitabine In Breast Cancer
Advanced/Metastatic Breast Cancer
Primary: Number of Participants With Objective Response Based on Data Review Committee's Assessment — 19; 0; 19 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=113 Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
Metastatic Androgen Independent Prostate Cancer
Primary: Safety of APC8015F by Review of Reported Adverse Events — 109 Participants
Phase 2 N=147 Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
Cervical Intraepithelial Neoplasia · Uterine Cervical Dysplasia
Primary: Pathological Response — 20; 24 participants
Phase 2 N=369 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
Anxiety Disorders
Primary: Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -10.1; -10.4; -10.8; -9.5 Units on scale
Phase 2 N=17 To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
Secondary Hypogonadism
Primary: Sperm Concentration — 0.54; 72.8; 3.00; 182.6 millions sperm/mL — p=0.118
Phase 2 N=22 AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Hodgkin's Disease
Primary: Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF — 0.68; 0.32 proportion of participants
Phase 2 N=5 Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Graft Rejection · Kidney Disease
Primary: Number of Patients With Renal Allograft Rejection — 5 participant
Phase 2 N=148 Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
HIV Infections
Primary: Proportion of Patients Without Failure of Strategy From Week 0 to Week 72 — 73; 55 Pourcentage — p=0.025
Phase 2 N=385 A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: American College of Rheumatology 20 Response (ACR20) at 6 Months — 23; 26; 23; 21 Participants
Phase 2 N=554 Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
Irritable Bowel Syndrome
Primary: Response of Overall IBS Symptom Relief - 50% Rule — 79; 61; 61; 78 Participants
Phase 2 N=72 ScanBrit Dietary Intervention in Autism
Autism · Autism Spectrum Disorder (ASD)
Primary: Change in Diet Groups Scores on One of Several Measures Used Against Pre-defined Statistical Thresholds as Evidence of Improvement. — -0.16715; 0.08235; -0.16176…
Phase 2 N=6 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Phase 2 N=20 A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
Liver Cirrhosis
Primary: Change From Baseline in Hepatic Venous Pressure Gradient (HVPG) at 0.5, 1, and 1.5 Hours Post Dose — 16.58; 18.33; 15.80; 0.33 mmHg
Phase 2 N=51 Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Phase 2 N=38 Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
Liver Diseases
Primary: Change From Baseline in Platelet Counts on Day 15 — 24.8; 54.0; 60.0 10^9/Liter